CME Presentations

Prostate Cancer for Urologists


Presentations


Speakers


CME Information

Enhancing Urology Care for Patients with Prostate Cancer: An Educational Series with Debates, Cases, Patient Perspectives, and Interactive Lectures


Einstein and Montefiore Logos

LEARNING OBJECTIVES

At the conclusion of this activity, participants will be able to:

Session 1: Utilizing Biomarkers to Navigate Treatment Decisions for Prostate Cancer Patients

  • Evaluate how molecular assay testing can provide clinically actionable information to select treatments or to assess risk and prognosis in patients with prostate cancer
  • Plan effective physician-patient communication strategies when counselling patients on prescribing specific tests

Session 2: Metastatic Prostate Cancer: Debating Challenging Treatment Decisions

  • Examine existing and emerging therapy choices for patients with hormone-sensitive prostate cancer
  • Select optimal therapies for patients with metastatic CRPC with and without visceral metastases
  • Review upcoming and emerging treatment strategies that are currently being investigated in phase III clinical trials

Session 3: Nonmetastatic Castration-Resistant Prostate Cancer: Implementing a New Treatment Paradigm in Urology Care – An Interactive Discussion through Case Studies

  • Evaluate when to initiate an antiandrogen agent in an asymptomatic patient with prostate cancer with a rising PSA
  • Review the approaches to managing side effects for nonmetastatic patients on antiandrogen therapy

Session 4: Nonmetastatic Castration Resistant Prostate Cancer: Emerging Therapeutic Strategies

  • Outline emerging strategies being studied for patients with nonmetastatic prostate cancer
  • Define the term “metastasis-free survival” for patients undergoing nonmetastatic treatments

ACKNOWLEDGEMENT

This activity is supported by independent educational grants from Astellas and Medivation, Inc., a Pfizer company; Bayer HealthCare Pharmaceuticals Inc.; Sanofi Genzyme; Genomic Health, Inc.; and Myriad Genetics, Inc.

TUITION

Complimentary

ACCREDITATION STATEMENT

The activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Albert Einstein College of Medicine and PlatformQ Health Education, LLC. Albert Einstein College of Medicine is accredited by the ACCME to provide continuing medical education for physicians.

CREDIT DESIGNATION STATEMENTS

Live Internet Activity
Albert Einstein College of Medicine designates this internet live activity for a maximum of 3.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Enduring Material
Albert Einstein College of Medicine designates this internet enduring material for a maximum of 3.5 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

OTHER CREDITS

The American Academy of Nurse Practitioners (AANP) and American Nurses Credentialing Center (ANCC) accept AMA PRA Category 1 Credit™ from organizations accredited by the ACCME.

DATE OF RELEASE/EXPIRATION

Live Internet Activity
Thursday, July 25, 2019 from 11:00 AM EST - 2:00 PM EST.
  • 11:00am - 12:00pm ET: Metastatic Prostate Cancer: Debating Challenging Treatment Decisions
  • 12:00pm - 1:00pm ET: Nonmetastatic Castration-Resistant Prostate Cancer: Implementing a New Treatment Paradigm in Urology Care – An Interactive Discussion through Case Studies
  • 1:00pm - 2:00pm ET: Nonmetastatic Castration Resistant Prostate Cancer: Emerging Therapeutic Strategies
Enduring Material

The enduring material will be available from July 22, 2019 to January 25, 2020.

INTENDED AUDIENCE

This activity is intended for urologists, medical oncologists, radiation oncologists and other health care professionals (internists, primary care physicians, pathologists, physicians-in-training, urology nurses, oncology nurses, nurse practitioners, pharmacists, physician assistants and nurse practitioners) involved and/or interested in the therapeutic management of patients with prostate cancer.

ESTIMATED TIME TO COMPLETE

This activity consists of four sessions, which should take approximately 3.5 hours to complete.

METHOD OF PARTICIPATION

There are no fees to participate in this activity. To receive credit, participants must (1) read the target audience, learning objectives, and disclosure statements, (2) complete the educational activity online, and (3) complete the posttest and activity evaluation. It is estimated that this module will take approximately 1 hour to complete. To receive AMA PRA Category 1 Credit™, participants must receive a minimum score of 70% on the posttest.

HARDWARE / SOFTWARE REQUIREMENTS

Participants will need a computer with a recent version of Adobe Flash installed, as well as an internet connection sufficient for streaming media.

FACULTY DISCLOSURE

The "Conflict of Interest Disclosure Policy" of Albert Einstein College of Medicine requires that faculty participating in any CME activity and anyone in a position to influence content disclose to the audience any relationship(s) with a pharmaceutical or equipment company. Any presenter whose disclosed relationships prove to create a conflict of interest, with regard to their contribution to the activity, will not be permitted to present.

The Albert Einstein College of Medicine also requires that faculty participating in any CME activity and anyone in a position to influence content disclose to the audience when discussing any unlabeled or investigational use of any commercial product, or device, not yet approved for use in the United States.

Presenter Disclosure
Neal D. Shore, MD, FACS Consulting Fees, Speakers Bureau, Fees for Non-CME/CE Services Received directly from a Commercial Interest or its Agent, Contracted Research: AbbVie, Astellas, Amgen, AZ, Bayer, BMS, Dendreon, Ferring, Genzyme, Genentech, Genomic Health, Invitae, Janssen, Merck, Myriad, Nymox, Pfizer, Sanofi, Tolmar
Adam S. Kibel, MD Consulting Fee: Bristol-Myers Squibb, Merck, Janssen, Profound, Insightec
William K. Oh, MD Consulting Fee: Astellas, AstraZeneca, Bayer, Janssen, Sanofi, Sema4, TeneoBio
Scott T. Tagawa, MD, MS Consulting Fee: Astellas, Abbvie, Amgen, Bayer, Clovis, Dendreon, Eisai, Endocyte, Genentech, Immunomedics, Janssen, Karyopharm, Medivation, Pfizer, QED, Sanofi, Seattle Genetics, Tolmar, Contracted Research: Abbvie, Amgen, Astellas, Atlab, Aveo, Bayer, BMS, Boehringer Ingelheim, Clovis, Dendreon, Endocyte, Genentech, Immunomedics, Janssen, Karyopharm, Lilly, Medivation, Merck, Millennium, Newlink, Novartis, Progenics, Rexahn, Sanofi, Seattle Genetics
Peer Reviewer Disclosures
Benjamin Gartrell, MD Has nothing to disclose relevant to this activity.
PlatformQ Health Education, LLC Disclosures
Agnes Lee, Medical Director Has nothing to disclose relevant to this activity.
Alissa Yost, Senior Program Manager Has nothing to disclose relevant to this activity.

CONTACT INFORMATION

Please send all inquiries to: Montefiore Medical Center, CCME, 3301 Bainbridge Avenue, Bronx, New York 10467, or via phone at (718) 920-6674, or via fax to (718) 798-2336, or via email to cme@montefiore.org.

For issues with your CME Certificate, please contact UroCareLive at 877-394-1306 or at Support@UroCareLive.com or OMedLive at 877-394-1306 or at Support@OMedLive.com.

DISCLAIMERS (if applicable):

The material is prepared based on a review of multiple sources of information but is not exhaustive of the subject matter. Therefore, health care professionals and other individuals should review and consider other publications and materials about the subject matter other than relying solely on the information contained in this material.

The information presented at this CME program represents the views and opinions of the individual presenters, and does not constitute the opinion or endorsement of, or promotion by Albert Einstein College of Medicine, UroCareLive, OMedLive, PlatformQ Health Education, LLC or the program grantor. Reasonable efforts have been made to present educational subject matter in a balanced, unbiased fashion and in compliance with regulatory requirements. Each participant must use his/her personal and professional judgment when considering further application of this information, particularly as it may relate to patient diagnostic or treatment decisions including, without limitation, FDA-approved uses and any off-label uses.